A randomized, open-label, controlled trial to evaluate the antimicrobial and surgical effect of CO 2 laser treatment in diabetic infected foot ulcers: DULCIS (diabetic ulcer, CO 2 laser, and infections) study

Debridement of fibrin and necrotic tissue from the ulcer surface is an important component of the treatment of diabetic ulcers. A possible alternative to standard lancets is represented by CO laser, which vaporizes necrotic tissues together with any pathogen. The present trial is aimed at verifying the effect of a CO laser on bacterial load in the debridement of infected diabetic foot ulcers. In this open-label randomized controlled trial (NCT02677779), patients with diabetes and an infected foot ulcers were randomized to either CO laser or traditional debridement. The reduction (%) of bacterial load with CO laser was significantly greater than in control group [-99.9 (-100.0; -90.0) vs. -50.0 (-96.0; -75.0), p = 0.049]. Similarly, a significantly greater reduction (%) of the fraction of ulcer area covered by fibrin was obtained in the intervention group [-84.1 (-95.0; -72.2) vs. -46.9 (-69.5; -40.8), p = 0.038]. Debridement of ulcers with CO laser significantly reduces bacterial load and fibrin-covered areas, and could be of help in the treatment of diabetic foot ulcer.